Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38- progenitor cells from patients with acute myeloid leukemia

被引:89
作者
Feuring-Buske, M [1 ]
Hogge, DE [1 ]
机构
[1] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada
关键词
D O I
10.1182/blood.V97.12.3882
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Efflux of Hoechst 33342 from normal hematopoietic cells identifies a "side population" (SP+) of negatively staining cells that, in the mouse, are largely CD34(-) and are enriched for primitive progenitors. To further characterize human SP+ cells, blood or bone marrow from 16 patients with acute myeloid leukemia (AML) was analyzed for their presence, immunophenotype, and cytogenetic and functional properties, and for the relation between SP phenotype and multidrug resistance-1 (MDR-1) expression. The mean percentages of SP+ and MDR+ cells was 8.1% (range, 0.5%-29.9%) and 12.8% (range, 0%-54.8%), respectively, with no correlation between the 2 values. The percentages of SPC cells that were CD34(+)CD38(-), CD34(+)CD38(+), or CD34(-) were 12% (range, 0.4%-50%), 25% (range, 0.5%-96%), and 63% (range, 4%-99%), Cytogenetically abnormal cells were always detected in the SP(-)CD34(+)CD38(-) and SP(+)CD34(-) fractions, and abnormal colonies (CFC), longterm culture-initiating cells (LTC-IC), and nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mouse leukemia-IC were detected in the former fraction. No progenitors were detected among SP(+)CD34(-) cells in any of these assays from 9 of 10 samples. In contrast, exclusively normal cells were detected in the SP(+)CD34(+)CD38(-) fraction from 9 of 15 samples, and CFC, LTC-IC, and multilineage engraftment in NOD/SCID mice from this subpopulation were also cytogenetically normal in 6 of 8, 6 of 7, and 2 of 2 cases studied, respectively. In contrast to murine studies, primitive progenitors are enriched among SP(+)CD34(+)CD38(-) cells from patients with AML. The molecular basis for Hoechst dye efflux is uncertain because it does not appear to be related to MDR-1 expression. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:3882 / 3889
页数:8
相关论文
共 47 条
  • [31] List AF, 1996, LEUKEMIA, V10, P937
  • [32] MEHROTRA B, 1995, BLOOD, V86, P1139
  • [33] Hematopoietic stem cells: Are they CD34-positive or CD34-negative?
    Nakauchi, H
    [J]. NATURE MEDICINE, 1998, 4 (09) : 1009 - 1010
  • [34] MDR1 GENE-EXPRESSION AND TREATMENT OUTCOME IN ACUTE MYELOID-LEUKEMIA
    PIRKER, R
    WALLNER, J
    GEISSLER, K
    LINKESCH, W
    HAAS, OA
    BETTELHEIM, P
    HOPFNER, M
    SCHERRER, R
    VALENT, P
    HAVELEC, L
    LUDWIG, H
    LECHNER, K
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (10) : 708 - 712
  • [35] Novel mechanisms of drug resistance in leukemia
    Ross, DD
    [J]. LEUKEMIA, 2000, 14 (03) : 467 - 473
  • [36] Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients
    SanMiguel, JF
    Martinez, A
    Macedo, A
    Vidriales, MB
    LopezBerges, C
    Gonzalez, M
    Cabaliero, D
    GarciaMarcos, MA
    Ramos, F
    FernandezCalvo, J
    Calmuntia, MJ
    DiazMediavilla, J
    Orfao, A
    [J]. BLOOD, 1997, 90 (06) : 2465 - 2470
  • [37] Reversible expression of CD34 by murine hematopoietic stem cells
    Sato, T
    Laver, JH
    Ogawa, M
    [J]. BLOOD, 1999, 94 (08) : 2548 - 2554
  • [38] DIFFERENTIAL EXPRESSION OF HOMEOBOX GENES IN FUNCTIONALLY DISTINCT CD34(+) SUBPOPULATIONS OF HUMAN BONE-MARROW CELLS
    SAUVAGEAU, G
    LANSDORP, PM
    EAVES, CJ
    HOGGE, DE
    DRAGOWSKA, WH
    REID, DS
    LARGMAN, C
    LAWRENCE, HJ
    HUMPHRIES, RK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (25) : 12223 - 12227
  • [39] INCREASED EXPRESSION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN GENE IN RELAPSED ACUTE-LEUKEMIA
    SCHNEIDER, E
    COWAN, KH
    BADER, H
    TOOMEY, S
    SCHWARTZ, GN
    KARP, JE
    BURKE, PJ
    KAUFMANN, SH
    [J]. BLOOD, 1995, 85 (01) : 186 - 193
  • [40] SHULTZ LD, 1995, J IMMUNOL, V154, P180